Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Allergan Plc (AGN)

Allergan Plc (AGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,503,972
  • Shares Outstanding, K 329,002
  • Annual Sales, $ 16,089 M
  • Annual Income, $ -5,271 M
  • 60-Month Beta 1.20
  • Price/Sales 3.95
  • Price/Cash Flow 5.26
  • Price/Book 1.09
Trade AGN with:
  • Price/Earnings ttm 10.94
  • Earnings Per Share ttm 17.64
  • Most Recent Earnings 5.22 on 02/10/20
  • Next Earnings Date 05/07/20
  • Annual Dividend & Yield 2.96 (0.00%)
  • Most Recent Dividend 0.740 on 04/15/20
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 4.24
  • Number of Estimates 1
  • High Estimate 4.24
  • Low Estimate 4.24
  • Prior Year 3.79
  • Growth Rate Est. (year over year) +11.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
181.21 +6.52%
on 04/09/20
196.45 -1.75%
on 05/06/20
+11.94 (+6.59%)
since 04/08/20
3-Month
158.67 +21.65%
on 03/18/20
202.21 -4.55%
on 02/12/20
-4.03 (-2.05%)
since 02/07/20
52-Week
114.27 +68.92%
on 06/17/19
202.21 -4.55%
on 02/12/20
+52.97 (+37.82%)
since 05/08/19

Most Recent Stories

More News
Diabetic Macular Edema Market in Western Europe to Register the Highest CAGR through 2027

The global is projected to register a sluggish expansion at 1.1% CAGR through 2027, according to a report by Future Market Insights (FMI). The report estimates the market to reach US$ 3710.2 Mn in 2017;...

ALIM : 9.74 (+5.18%)
AGN : 193.02 (+0.02%)
BAYRY : 16.8650 (+3.15%)
VRX.TO : 30.80 (-3.33%)
Global Diabetic Macular Edema Market: Increasing Economic Burden Diabetes to Drive the Market, observes FMI

The global is projected to register a sluggish expansion at 1.1% CAGR through 2027, according to a report by Future Market Insights (FMI). The report estimates the market to reach US$ 3710.2 Mn in 2017;...

ALIM : 9.74 (+5.18%)
AGN : 193.02 (+0.02%)
BAYRY : 16.8650 (+3.15%)
VRX.TO : 30.80 (-3.33%)
Global Refractive Surgical Devices MarketSize, Share, Value, and Competitive Landscape 2020

The Refractive Surgical Devices market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape,...

ABT : 122.42 (+2.02%)
AGN : 193.02 (+0.02%)
CZMWF : 150.0000 (unch)
STAA : 127.35 (+7.19%)
TOPCF : 13.7000 (-3.39%)
VRX.TO : 30.80 (-3.33%)
Ophthalmic Steroids Drug Market Size,Growth 2020 Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2026

Market Survey: COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms...

ALIM : 9.74 (+5.18%)
AGN : 193.02 (+0.02%)
BAYRY : 16.8650 (+3.15%)
GSK : 38.20 (+1.33%)
NVS : 88.85 (+1.16%)
REGN : 504.88 (+0.09%)
VRX.TO : 30.80 (-3.33%)
Dry Eye Syndrome Treatment Market 2021 SWOT Analysis (PDF Report) & Key Business Strategies by Leading Players |Novartis AG, Allergan, Alcon

The studies on worldwide Dry Eye Syndrome Treatment market evaluate the capabilities, organizations, infrastructure, determines measures to attain success. Due to an, the study at permits the traders to...

ABT : 122.42 (+2.02%)
AKRX : 0.0900 (-51.01%)
AGN : 193.02 (+0.02%)
NVS : 88.85 (+1.16%)
VRX.TO : 30.80 (-3.33%)
Legendary CEO David Pyott to host a Vanguard Network "Learning From Experience" Candid Discussion on April 21

NEW YORK, April 14, 2021

AGN : 193.02 (+0.02%)
Global Cataract Surgery Devices Market 2020 Key Players, Regions, Company Profile, Growth Opportunity and Challenges by 2026

offers detailed coverage of the market which includes industry chain structure, definitions, applications, and type. The report delivers the correct and tactical analysis of the market share, growth factors,...

AGN : 193.02 (+0.02%)
CZMWF : 150.0000 (unch)
NVS : 88.85 (+1.16%)
STAA : 127.35 (+7.19%)
VRX.TO : 30.80 (-3.33%)
Otoscope Devices Market Research Report by Type, by Distribution Channel – Global Forecast to 2025 – Cumulative Impact of COVID-19

The Global is Segmented on the lines of End Users Analysis, Product Analysis, Application Analysis and Regional Analysis. By End Users Analysisthis market is segmented on the basis ofConsumer Sector,...

AGN : 193.02 (+0.02%)
CYNO : 66.15 (+0.23%)
NSRGY : 116.6750 (+0.69%)
ELOS : 11.00 (unch)
VRX.TO : 30.80 (-3.33%)
ZLTQ : 56.48 (unch)
Booming CAGR of 12.9%, Irritable Bowel Syndrome Treatment Market To Surpass US$ 2,300 Million Threshold By 2027 | CMI

AGN : 193.02 (+0.02%)
ALPMF : 14.6700 (-2.20%)
GSK : 38.20 (+1.33%)
NVS : 88.85 (+1.16%)
SCMP : 18.05 (+0.28%)
SGYP : 0.03 (-52.00%)
VRX.TO : 30.80 (-3.33%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allergan plc and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - April 13, 2021) - , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allergan plc ("Allergan"...

AGN : 193.02 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 194.42
1st Resistance Point 193.72
Last Price 193.02
1st Support Level 191.98
2nd Support Level 190.94
3rd Support Level N/A

See More

52-Week High 202.21
Last Price 193.02
Fibonacci 61.8% 168.62
Fibonacci 50% 158.24
Fibonacci 38.2% 147.86
52-Week Low 114.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar